Novel biallelic FA2H mutations in a Japanese boy with fatty acid hydroxylase-associated neurodegeneration

2020 ◽  
Vol 42 (2) ◽  
pp. 217-221
Author(s):  
Masahiro Kawaguchi ◽  
Takayuki Sassa ◽  
Hiroyuki Kidokoro ◽  
Tomohiko Nakata ◽  
Kohji Kato ◽  
...  
Molecules ◽  
2020 ◽  
Vol 25 (10) ◽  
pp. 2286
Author(s):  
Lingjun Yu ◽  
Vimmy Khetrapal ◽  
Fengquan Liu ◽  
Liangcheng Du

The biocontrol agent Lysobacter enzymogenes OH11 produces several structurally distinct antibiotic compounds, including the antifungal HSAF (Heat Stable Antifungal Factor) and alteramides, along with their 3-dehydroxyl precursors (3-deOH). We previously showed that the 3-hydroxylation is the final step of the biosynthesis and is also a key structural moiety for the antifungal activity. However, the procedure through which OH11 regulates the 3-hydroxylation is still not clear. In OH11, the gene orf3232 was predicted to encode a TetR regulator (LeTetR) with unknown function. Here, we deleted orf3232 and found that the LeTetR mutant produced very little HSAF and alteramides, while the 3-deOH compounds were not significantly affected. The production of HSAF and alteramides was restored in orf3232-complemented mutant. qRT-PCR showed that the deletion of orf3232 impaired the transcription of a putative fatty acid hydroxylase gene, orf2195, but did not directly affect the expression of the HSAF biosynthetic gene cluster (hsaf). When an enzyme extract from E. coli expressing the fatty acid hydroxylase gene, hsaf-orf7, was added to the LeTetR mutant, the production of HSAF and alteramides increased by 13–14 fold. This study revealed a rare function of the TetR family regulator, which positively controls the final step of the antifungal biosynthesis and thus controls the antifungal activity of the biocontrol agent.


2010 ◽  
Vol 17 (12) ◽  
pp. 1295-1305 ◽  
Author(s):  
Yogan Khatri ◽  
Frank Hannemann ◽  
Kerstin M. Ewen ◽  
Dominik Pistorius ◽  
Olena Perlova ◽  
...  

2016 ◽  
Vol 133 ◽  
pp. 35-42 ◽  
Author(s):  
Hyun-Hee Jang ◽  
Sun-Mi Shin ◽  
Sang Hoon Ma ◽  
Ga-Young Lee ◽  
Young Hee Joung ◽  
...  

1999 ◽  
Vol 261 (1) ◽  
pp. 156-162 ◽  
Author(s):  
Renaud Le Bouquin ◽  
Franck Pinot ◽  
Irène Benveniste ◽  
Jean-Pierre Salaün ◽  
Francis Durst

2011 ◽  
Vol 507 (1) ◽  
pp. 75-85 ◽  
Author(s):  
Hazel M. Girvan ◽  
Adrian J. Dunford ◽  
Rajasekhar Neeli ◽  
Idorenyin S. Ekanem ◽  
Timothy N. Waltham ◽  
...  

2020 ◽  
Vol 26 (68) ◽  
pp. 15910-15921
Author(s):  
Julia Armbruster ◽  
Mathilde Steinmassl ◽  
Christina A. Müller Bogotá ◽  
Gabriele Berg ◽  
Bernd Nidetzky ◽  
...  

PPAR Research ◽  
2009 ◽  
Vol 2009 ◽  
pp. 1-20 ◽  
Author(s):  
James P. Hardwick ◽  
Douglas Osei-Hyiaman ◽  
Homer Wiland ◽  
Mohamed A. Abdelmegeed ◽  
Byoung-Joon Song

Fatty liver disease is a common lipid metabolism disorder influenced by the combination of individual genetic makeup, drug exposure, and life-style choices that are frequently associated with metabolic syndrome, which encompasses obesity, dyslipidemia, hypertension, hypertriglyceridemia, and insulin resistant diabetes. Common to obesity related dyslipidemia is the excessive storage of hepatic fatty acids (steatosis), due to a decrease in mitochondria -oxidation with an increase in both peroxisomal -oxidation, and microsomal -oxidation of fatty acids through peroxisome proliferator activated receptors (PPARs). How steatosis increases PPAR activated gene expression of fatty acid transport proteins, peroxisomal and mitochondrial fatty acid -oxidation and -oxidation of fatty acids genes regardless of whether dietary fatty acids are polyunsaturated (PUFA), monounsaturated (MUFA), or saturated (SFA) may be determined by the interplay of PPARs and HNF4 with the fatty acid transport proteins L-FABP and ACBP. In hepatic steatosis and steatohepatitis, the -oxidation cytochrome P450CYP4Agene expression is increased even with reduced hepatic levels of PPAR. Although numerous studies have suggested the role ethanol-inducibleCYP2E1in contributing to increased oxidative stress,Cyp2e1-null mice still develop steatohepatitis with a dramatic increase inCYP4Agene expression. This strongly implies thatCYP4Afatty acid -hydroxylase P450s may play an important role in the development of steatohepatitis. In this review and tutorial, we briefly describe how fatty acids are partitioned by fatty acid transport proteins to either anabolic or catabolic pathways regulated by PPARs, and we explore how medium-chain fatty acid (MCFA)CYP4Aand long-chain fatty acid (LCFA)CYP4F-hydroxylase genes are regulated in fatty liver. We finally propose a hypothesis that increasedCYP4Aexpression with a decrease inCYP4Fgenes may promote the progression of steatosis to steatohepatitis.


Sign in / Sign up

Export Citation Format

Share Document